SCHEMBL22835429

SCHEMBL22835429

O=Cc1cc(Br)c(OC(F)(F)F)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
CYP3A4 P08684 3/20 0.53
PRKDC P78527 2/20 0.53
ALOX15 P16050 2/20 0.53
MAPT P10636 2/20 0.53
KDM4E B2RXH2 1/20 0.53
HSD17B10 Q99714 1/20 0.53
ERN1 O75460 6/20 0.41
TDP1 Q9NUW8 2/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
HIF1A Q16665 1/20 0.32
TXNRD1 Q16881 1/20 0.32
TXNRD3 Q86VQ6 1/20 0.32
TXNRD2 Q9NNW7 1/20 0.32
GAA P10253 1/20 0.31
HTT P42858 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
XDH P47989 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29502287 1.00 ALDH1A1 (0.53) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL1572262 0.80 ALDH1A1 (0.76) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL29502284 0.80 ALDH1A1 (0.76) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL29502581 0.79 MAPT (0.53) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL22835646 0.79 MAPT (0.53) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL4855795 0.79 ALDH1A1 (0.44) ALDH1A1CYP3A4ALOX15MAPTTDP1
SCHEMBL30412897 0.77 ALDH1A1 (0.55) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL26129805 0.77 ALDH1A1 (0.45) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL29751494 0.77 ALDH1A1 (0.45) ALDH1A1CYP3A4PRKDCALOX15MAPT
SCHEMBL22835614 0.77 MAPT (0.56) ALDH1A1CYP3A4PRKDCALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 US disclosed
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-04-17 US disclosed
US-12150995-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-11-26 US disclosed
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-02-22 US disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 EP disclosed
CN-116867758-A IRAK degradation agents and uses thereof 凯麦拉医疗公司 2023-10-10 CN disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-30 US disclosed
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-02 US disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 WO disclosed
CN-114502158-A IRAK degradation agent and application thereof 凯麦拉医疗公司 2022-05-13 CN disclosed
EP-3989966-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-05-04 EP disclosed
WO-2020264499-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 ALDH1A1 4348/4885CYP3A4 3598/4885PRKDC 1590/4885
US-20250121073-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885CYP3A4 2542/4885PRKDC 724/4885
US-12150995-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885CYP3A4 2542/4885PRKDC 724/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 ALDH1A1 3721/4885CYP3A4 1164/4885PRKDC 2458/4885
US-20240059674-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885CYP3A4 2542/4885PRKDC 724/4885
US-20230069104-A1 IRAK DEGRADERS AND USES THEREOF IRAK4, IRAK2, IRAK3 ALDH1A1 3918/4885CYP3A4 3299/4885PRKDC 842/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885CYP3A4 2542/4885PRKDC 724/4885
US-20230101353-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 2776/4885CYP3A4 2542/4885PRKDC 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.